Sebia, Inserm Partner to Develop, Commercialize Hemoglobin Disease Diagnostic | GenomeWeb

NEW YORK (GenomeWeb News) – French electrophoresis firm Sebia today announced a deal with the French National Institute of Health and Medical Research, or Inserm, to develop and commercialize a test to measure free alpha globin chains in beta-thalassaemic patients.

The deal, which also involved Inserm's technology transfer firm, Inserm Transfert, calls for Sebia to support Inserm's development of the test. Sebia will have the right to acquire exclusive rights to develop the test on an industrial scale and to market it globally.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.